Dr. Adjei is a consultant in medical oncology at Mayo Clinic and professor of oncology and pharmacology in the Mayo College of Medicine. He is the director of the Early Cancer Therapeutics Program across all three Mayo sites. He is also director of global oncology and director of the Lung Cancer program across all three Mayo Clinic sites. He is the principal investigator of the Mayo Clinic phase I and phase II National Cancer Institute grants. Dr. Adjei has served on a number of AACR, ASCO and NCI Committees. He was vice-chair of the North Central Cancer Treatment Group and Lung Cancer Committee Chair. He is currently co-chair of the Thoracic Malignancies Steering Committee and was a member of Subcommittee A which reviews NCI Cancer Centers. He is the editor-in-chief of the
Dr. Adjei’s research is focused on experimental therapeutics and clinical drug development. He received the first ASCO Drug Development Research Professorship 2012-2017, in recognition of his mentorship and his work in cancer drug development. He has authored 265 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapeutics/phase II trials of lung cancer.
Top of page
Nilofer S. Azad, MD
Associate Professor, Oncology Research
John Hopkins University
Dr. Azad is an associate professor of oncology and a member of the Gastrointestinal Oncology Program within the Sidney Kimmel Comprehensive Cancer Center (SKCCC). She completed her fellowship in medical oncology at the National Cancer Institute and became a member of its faculty in July 2008. Since joining the faculty of the SKCCC at Johns Hopkins, Dr. Azad is the PI of numerous early phase clinical trials in solid tumors and gastrointestinal cancers. Dr. Azad is a clinically active medical oncologist and is the coleader of the NCI funded UM1 Developmental Therapeutics clinical research program at the SKCCC. She is a member of both the Epigenetics and Colon Cancer Stand Up 2 Cancer Dream Teams, serving as a principal on the latter. She is a member of the NCI Colon Cancer Task Force, the Advisory Board of the Biden Cancer Initiative, and the Executive Board of The Cholangiocarcinoma Foundation, among others.
Dr. Azad’s laboratory is dedicated to translational research in drug development that will form the foundation of future clinical trials. Her research focuses on epigenetic alterations in cancer cells, which are changes in gene expression due to potentially reversible modifications of DNA. Her lab is currently investigating drugs that work through epigenetic mechanisms as well as epigenetic molecular differences in tumors that may change the efficacy of treatment, as well as the intersection of these agents with immunotherapy. These preclinical studies are designed to move directly into early phase clinical trials, with strong laboratory correlates that will be used to further hone the therapeutic regimens, as a quintessential example of bench-to-bedside medicine.
“Bi-directional mentorship combined with hard work makes all the difference for career advancement.”
Top of page
William T. Beck, PhD
UIC Distinguished Professor Emeritus, Biopharmaceutical Sciences
University of Illinois at Chicago
William T. Beck has over 40 years in academic biomedical research and administration, much experience on federal and other scientific advisory boards and grant review panels, and has held leadership positions in national organizations. He has served as cancer center director, department head, and associate dean for research at the University of Illinois at Chicago. He was also elected: member of the board of the AACR; fellow of the AAAS; and member-at-large, chair, and secretary of the Pharmaceutical Sciences Section (Section S) of the AAAS, among others. Importantly, Dr. Beck has much experience mentoring students, fellows, and junior and senior faculty.
Dr. Beck’s grant-funded research focused on molecular mechanisms of anticancer drug resistance, with emphasis on developing novel therapeutic targets in ovarian and breast cancers. To this end, he and his colleagues identified two pre-mRNA splicing factors that are overexpressed in ovarian and breast cancers compared to normal ovarian and breast tissue, and whose inhibition suppresses the growth of these cancers in vitro and in mice bearing tumors. Accordingly, they developed an NIH-funded cell-based high-throughput screen to find small molecule drugs to inhibit these proteins, identifying one FDA-approved drug.
"Assume nothing. Also organize a mentoring committee to help you navigate career choices."
Top of page
Carolyn C. Compton, MD, PhD
Professor of Pathology, School of Life Science
Arizona State University, Mayo Clinic School of Medicine
Carolyn Compton, MD, PhD, is an academic pathologist specializing in gastrointestinal disease. She is a professor of life sciences at Arizona State University, a professor of laboratory medicine and pathology at the Mayo Clinic School of Medicine, and a professor of pathology at the Johns Hopkins Medical Institutions. She is the chief medical officer of both the National Biomarker Development Alliance and the Complex Adaptive Systems Initiative. She is the chair of the Precision Medicine Core of the AJCC and the chair of the Preanalytics for Precision Medicine Project Team of the College of American Pathologists. She serves as the editor-in-chief of the Nature Review journal Current Pathobiology Reports. She is a former professor of pathology at Harvard Medical School, chief of gastrointestinal pathology at Massachusetts General Hospital, and pathologist-in-chief of the Boston Shriners Children's Hospital. More recently she has served as the CEO and president of the Critical Path Institute (2012), the director of the Office of Biorepositories and Biospecimen Research and the director of the Innovative Molecular Analysis Technologies program at the National Cancer Institute (2005-2011), and the Strathcona professor and chair of the Department of Pathology at McGill University and pathologist-in-chief of the McGill University Health Center.
"Exciting opportunities are everywhere - academics, government, industry. Don't be afraid to step out of your comfort zone for a chance to make a difference for cancer patients."
Senior Director, Head of UK Oncology Bioscience
Dr. Critchlow is the head of UK Bioscience in the Oncology IMED of AstraZeneca based in Cambridge, UK. She currently leads a group of ~80 scientists delivering novel oncology drugs into the clinic. Their work covers a range of areas of cancer biology including DNA damage response, tumor drivers and resistance and immuno-oncology. In her role, Dr. Critchlow is accountable for ensuring delivery of biology data to support the AZ oncology portfolio from target identification to delivering phase II proof of concept data. Her role encompasses a range of activities including managing the department, line managing scientists, sitting on global cross-portfolio teams and acting as biology lead on drug discovery projects.
“Make the most of every opportunity that comes your way to build new skills and experience. I also recommend building your network and knowledge beyond your immediate scientific area of interest - it can be invaluable at a later date.”
William S. Dalton, MD, PhD
Founder and Executive Chair
Dr. Dalton is founder and executive chair of M2Gen, a national biotechnology subsidiary of the Moffitt Cancer Center. He is the past president, CEO, and center director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to joining Moffitt, Dr. Dalton was the dean of the University of Arizona College of Medicine. His research interests include development of information systems to allow aggregation, organization, and sharing of patient data in real time to enhance discovery and delivery of evidenced-based precision medicine. For his leadership in personalized medicine, Dr. Dalton was the 2010 recipient of the Personalized Medicine Coalition's National Leadership in Personalized Medicine Award. Dr. Dalton's basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and computer/information networking. He serves on numerous non-profit boards, including the National Board of the Leukemia and Lymphoma Society; he is the past-chair of the Personalized Medicine Coalition and is the current board chair of the Institute of Human and Machine Cognition. He is also the past-president of the Association of American Cancer Institutes.
"When considering you career options, choose on the basis of where will you have the greatest impact and the most fun."
Laboratory Director/President, Frederick National Laboratory for Cancer Research
Leidos Biomedical Research Inc.
Dr. Dmitrovsky became laboratory director of the Frederick National Laboratory for Cancer Research and president of Leidos Biomedical Research in 2017. This National Laboratory combats AIDS, cancer, infectious diseases and emerging health challenges. He is the former provost and executive vice president of the University of Texas MD Anderson Cancer Center. He most recently served as the Olga Keith and Harry Carothers Weiss distinguished university chair and American Cancer Society (ACS) professor at The University of Texas MD Anderson Cancer Center. Before joining that center, he chaired the Pharmacology and Toxicology Department and was interim dean at the Geisel School of Medicine at Dartmouth. He also chaired the Board of Scientific Counselors for Clinical Sciences and Epidemiology for the National Cancer Institute.
At MD Anderson, Dr. Dmitrovsky oversaw robust undergraduate and graduate programs and more than 4,000 clinical trials. He also served as principal investigator of their National Institutes of Health-funded Cancer Center Core Grant, MD Anderson's largest federal grant. In addition, Dr. Dmitrovsky fostered collaborations with 33 sister institutions in 23 countries, including the launching of a pain medicine initiative for cancer patients in Ethiopia, a country of 90 million with few pain specialists. His team created a Provost Protégé Program for faculty members of diverse backgrounds, broadened the reach of the Women Faculty Office to add Minority Faculty Inclusion to its mission, and implemented innovative programs to support the training and scholarship of faculty, research nurses, students and fellows. His team also implemented a computer-based tobacco prevention and cessation program for the Houston Independent school system. His translational work that established successful all-trans-retinoic acid differentiation therapy for acute promyelocytic leukemia became FDA approved. He was recognized for this with the 2016 American Society of Clinical Oncology and ACS Award and Lecture.
Dr. Dmitrovsky graduated from Harvard University and Cornell University Medical College. He completed his residency in internal medicine at New York Hospital-Memorial Sloan-Kettering Cancer Center and oncology fellowship at the National Cancer Institute. He is a physician-scientist and oncologist, who directs a laboratory focused on molecular pharmacology. He is a member of the American Society for Clinical Investigation (ASCI), the Association of American Physicians (AAP) and a fellow of the American Association for the Advancement of Science (AAAS).
“I find my work as meaningful today as when I began my career as a physician-scientist. The challenge in making a discovery is as exciting to me now as on my first day working in a laboratory. As an oncologist and cancer scientist, I head a laboratory focused on molecular pharmacology. Our team is finding new ways to combat deadly cancers, like lung cancer. But I did not create my career in isolation. Along the way, many teachers, colleagues and mentors guided me. To any early career investigator, I would say how important it is to learn what you are passionate about and pursue that interest in a single-minded way. Also, search for mentors, who can help you during your journey. And look for sponsors, who will advocate for you and introduce you to opportunities that will make your career especially fulfilling. If you are fortunate, they will be counted among your closest professional colleagues.”
Director, Division of Cancer Treatment and Diagnosis
National Cancer Institute, National Institutes of Health
Dr. Doroshow has been the deputy director for clinical and translational research of the National Cancer Institute since 2011, and the director of NCI's Division of Cancer Treatment and Diagnosis since 2004. He continues to pursue his own research program as a senior investigator in the Developmental Therapeutics Branch of the NCI's intramural Center for Cancer Research. He is the author of over 500 full-length publications in the areas of molecular pharmacology, the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to solid tumors. From 1983 to 2004, Dr. Doroshow was the chairman of the City of Hope Comprehensive Cancer Center's Department of Medical Oncology and Therapeutics Research, and associate cancer center director for clinical investigation. He has served on the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration, the Medical Oncology Board of the American Board of Internal Medicine, and as chair of two NIH study sections: Experimental Therapeutics II and Subcommittee A, Cancer Centers. He is currently a member of the National Cancer Policy Forum of the National Academy of Medicine of the National Academies of Science. Dr. Doroshow received his AB degree magna cum laude from Harvard College in 1969 and graduated from Harvard Medical School in 1973. Following an internal medicine residency at the Massachusetts General Hospital, he completed a fellowship in medical oncology at the Medicine and Clinical Pharmacology Branches of the National Cancer Institute, NIH.
"Having the opportunity to pursue focused scientific interests in depth and over a prolonged time span in both the lab and clinic has been the most rewarding part of my career."
Top of page
Wafik S. El-Deiry, MD, PhD, FACP
Associate Dean for Oncologic Sciences, Director, Joint Program in Cancer Biology
Warren Alpert Medical School, Brown University and Affiliated Hospitals
Providence, Rhode Island
Dr. El-Deiry is associate dean for oncologic sciences at the Warren Alpert Medical School and director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is a professor of pathology and laboratory medicine, professor of medical science, and Mencoff Family university professor at Brown. He previously served as deputy director for translational research, co-leader of the Molecular Therapeutics Program, professor of oncology, and the William Wikoff Smith endowed chair in cancer research at Fox Chase Cancer Center. From 2010 through 2014 Dr. El-Deiry was the Rose Dunlap professor of medicine and chief of hematology-oncology at Penn State. In 2009, El-Deiry became an American Cancer Society research professor. He earned MD/PhD degrees from University of Miami School of Medicine and completed internal medicine residency and medical oncology fellowship at the Johns Hopkins Hospital and the Johns Hopkins Oncology Center. El-Deiry has >400 peer-reviewed publications and five edited books. In 2019, his H-index is 111 and he has >66,000 citations in Google Scholar. A practicing oncologist, his scientific expertise is in cell death, drug resistance in cancer and drug discovery and development. Dr. El-Deiry has trained many students and postdoctoral fellows, physician-scientists, and continues to mentor junior scientists and faculty in basic and translational cancer research.
"Be persistent, train in the best possible environment with the best mentors, present your work at every opportunity, keep up the publications, collaborate and work in areas where you enjoy the science and translation. Be critical of your own work. Listen to critical comments from reviews, and listen to advice from others. Set ambitious goals and work towards meeting them. Set a good example for others at your institution and within your research program. Keep a work-life balance. Help others and serve the community. For physician-scientists, become specialized, keep doing clinical work and try to make a unique contribution through the research and your skill-set."
Top of page
Sharon H. Giordano, MD, MPH, FASCO
Professor and Chair, Department of Health Services Research
The University of Texas MD Anderson Cancer Center
Dr. Sharon Giordano is a medical oncologist specializing in the care of patients with breast cancer. She serves as the chair of the Department of Health Services Research, professor in the Department of Breast Medical Oncology, and the Hubert L. and Oliver Stringer distinguished professor in cancer research at The University of Texas MD Anderson Cancer Center. Her work focuses on research using large databases to study quality of health care delivery, disparities, and outcomes for breast cancer patients. She serves on the NCCN Breast Cancer Panel, as a Komen Scholar, cochairs ASCO's Breast Cancer Guidelines Advisory Group, and cochairs ASCO's treatment guidelines on HER2 positive breast cancer. She has research funding from NCI, Komen, CPRIT, BCRF, and AHRQ and has published over 200 peer-reviewed publications. Dr. Giordano has received awards for teaching and successfully mentored trainees on ASCO Young Investigator Grants, DOD grants and NCI K grants.
"Your career is a marathon, not a sprint."
Top of page
Global Head Johnson & Johnson External Innovation
Johnson & Johnson
Raritan, New Jersey
Dr. Hait leads the external sourcing and creation of transformational innovation to help Johnson & Johnson achieve its mission to change the trajectory of health for humanity. He works on building an enterprise-wide external R&D pipeline, creating innovative solutions that utilize J&J's excellence in pharmaceuticals, medical devices and consumer products. His team strives to identify disruptive technologies and cutting-edge early innovations in disease areas of emphasis at J&J, to eliminate disease through prevention, interception and cures.
Dr. Hait joined J&J in 2007 and served as global therapeutic area head for oncology from 2009 to 2011, and then as global head, Janssen Research and Development, from 2011 through 2018. Before that, he was the founding director of The (Rutgers) Cancer Institute of New Jersey. From 1993 to 2007, he was professor of medicine and pharmacology and associate dean for oncology programs at the University of Medicine and Dentistry of New Jersey -- Robert Wood Johnson Medical School.
Dr. Hait joined the Yale University School of Medicine faculty in 1984 and became associate professor of medicine and pharmacology, chief of the Division of Medical Oncology, associate director of the Yale University Comprehensive Cancer Center, director of the Breast Cancer Unit and co-director of the Lung Cancer Unit. He is board certified in internal medicine and medical oncology.
He devoted time to numerous advisory and editorial boards, served in a range of scientific functions, societies and committees, was elected president of the American Association for Cancer Research (2007 – 2008) and has received numerous awards and honors.
Top of page
Associate Chief, Investigational Drug Branch; Program Director, Experimental Therapeutics Clinical Trials Network, Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis
National Cancer Institute
Dr. Ivy is the associate chief (2005-present) of the Investigational Drug Branch (IDB), which is part of the Cancer Therapy Evaluation Program (CTEP) (1997-present) in the Division of Cancer Treatment and Diagnosis of the National Cancer Institute. She received her medical and subspecialty training at Tulane University Medical School, Vanderbilt University Medical Center and the National Cancer Institute, respectively. During her fellowship she worked in the Molecular Pharmacology Section which focused on the molecular mechanisms of drug resistance mediated by the ABC transporter genes in models of breast cancer and carcinogenesis. She is currently an adjunct professor of pediatrics at the George Washington University School of Medicine on the faculty at Children’s National Medical Center where she attends in the leukemia clinic.
In her role as associate chief of IDB she has supervised nine senior investigators and multiple fellows in the Developmental Chemotherapy Section which became Experimental Therapeutics Section I with a focus on inhibitors of DNA repair and damage response including PARPi, Wee1, DNA-PKi, angiogenesis inhibitors, heat shock protein 90 inhibitors and inhibitors of receptor:ligand interactions including disregulated cancer stem cell embryonic signaling pathways for hedgehog, notch, wnt and others. She has received 15 NIH Merit Awards for her work on specialized studies in patients with hepatic and renal dysfunction using cancer investigational therapeutics, use of novel imaging techniques for the evaluation of investigational agents in early clinical trials and most recently for assisting the in the implementation of the Investigational Drug Steering Committee (IDSC) which is part of the Clinical Trials Working Group, an NCI initiative for improving NCI-sponsored clinical trials in the US. She serves on the IDSC coordination team as well as starting the angiogenesis task force and NCI chairing the Clinical Trial Design and Pharmacology Task Forces for Early Clinical Trials.
She serves as the program director for the Experimental Therapeutics Clinical Trials Network which is funded by NCI. She serves on the Scientific Committee for the AACR-NCI-EORTC Molecular Targets Conference and for the Experimental Therapeutics Section for ASCO and AACR. She has presented both nationally and internationally on topics related to early therapeutics development, early phase clinical trial design, biomarker development, the role of anti-angiogenic agents in cancer therapy, clinical trials for patients with hepatic and renal dysfunction.
She has participated in the development of over 60 investigational agents, co-developed and monitored greater than 100 early phase clinical trials, established the NCI organ dysfunction working group that has evaluated 20 plus drugs, co-authored or authored 208 manuscripts and 15 book chapters in her areas of interest in experimental therapeutics. She has received the Margaret B. and Cyril A. Shulman Distinguished Service Award for starting the general pediatric clinic for medically indigent children at Bread for the City/Zaccheus Free Clinic and supports Doorways for women and children who are victims of abuse and established the Woody and Mickey Healthy Pet Fund that supports the Animal Welfare League of Arlington, Virginia.
“Do what you love and love what you do! Make a difference in the lives of cancer patients.”
Professor of Oncology
Dr. Kaur has 30 years of experience mentoring minority researchers and my passion for training the next generation of cancer researchers. She have been on the K12 advisory board for Mayo Clinic since 2000. Dr. Kaur has Master's Faculty Privileges in Clinical and Translational Sciences. In addition she has served on the trans NIH and HHS Disparities Progress Reviews and serve on numerous journal review boards. She has been funded as a health disparities researcher since 2000 and serve as faculty for a course for minority junior researchers in collaboration with the Roswell Park Cancer Institute since 2014.
"The key to successful collaborations is laying out roles and responsibilities and realistic timelines."
Director, University of Florida Health Cancer Center
University of Florida
Dr. Licht is the director of the UF Health Cancer Center, and professor of medicine and biochemistry at the University of Florida. For over 25 years, his laboratory has studied aberrant transcriptional regulation as a cause of hematologic malignancy. This has included the molecular biology of acute promyelocytic leukemia and transcriptional mechanisms and targets of PLZF transcription factor. More recently he has studied chromatin changes and gene expression mediated by the NSD2 protein overexpressed in a subset of multiple myeloma and mutated in childhood ALL, and chromatin changes mediated by EZH2 in lymphoma and KDM6A in multiple myeloma. For the past 11 years Dr. Licht served as the principal investigator of a Leukemia Society SCOR grant on chromatin mechanisms in hematologic malignancies. He also serves as co-PI of the Chicago Area Physical Science-Oncology Center, also centered on aberrant chromatin regulation and has led a MMRF program grant on epigenetics in multiple myeloma. Dr. Licht is the chair of the AACR Taskforce on Hematological Malignancies. Dr. Licht is currently chair of the Mechanisms of Cancer Therapeutics-1 NIH Study Section. He has trained a dozen PhD and MD-PhD students and more than 30 postdoctoral fellows.
“Basic and translational cancer research is one of the most exciting fields you can enter; every day is a new challenge. Its key to think broadly, innovate, find mentors to guide you and focus you and consider potential impact of your work on human health. Collaboration and engagement is key; no-one can solve the problems of cancer alone.”
David Malkin, MD
NIH Distinguished Investigator, Head, Signaling and Oncogenesis Section Deputy Director
National Cancer Institute
Dr. Lowy has two main research areas. One focuses on basic and translational aspects of human papillomavirus infection. His joint research with John Schiller in the Laboratory of Cellular Oncology (LCO) has identified many aspects of the human papillomavirus (HPV) life cycle, developed technology underlying the FDA-approved HPV vaccines, and elucidated mechanisms for the high efficacy of the vaccines. The second area focuses on cancer genes, currently emphasizing the DLC1 tumor suppressor, which encodes a Rho-GAP that is down-regulated in a wide variety of cancers, leading to the high Rho activity seen in many advanced cancers. This research has identified important scaffold functions for DLC1, including protein-protein interactions that contribute to the regulation of its activity and its role as a tumor suppressor, and identified kinases that activate and inactivate the functions of DLC1 and the mechanisms by which they do so.
Professor, Department of Pediatrics
The Hospital for Sick Children, University of Toronto
Toronto, Ontario, Canada
Dr. Malkin is professor of pediatrics and medical biophysics in the Faculty of Medicine, University of Toronto. He is a pediatric oncologist, director of the Cancer Genetics program, and a senior scientist in the Genetics and Genome Biology Program at The Hospital for Sick Children in Toronto. He is co-director of the SickKids Cancer Sequencing (KiCS) program which integrates and translates next generation sequencing into clinical care of children with cancer, and director of the pan-Canadian multi-institutional PRecision Oncology For Young peopLE (PROFYLE) initiative which is establishing a pipeline to incorporate next generation sequencing into novel clinical trials (‘precision oncology’) for children and young adults with hard-to-treat cancers across Canada.
Dr. Malkin’s research program focuses on genetic and genomic mechanisms of childhood cancer susceptibility which he has explored particularly in the context of TP53 and Li-Fraumeni syndrome. Recently, his work has addressed the application of genomics to develop rational clinical surveillance and treatment guidelines for children and adults at genetic ‘high risk’ for cancer. His research has been funded by the Terry Fox Research Institute, Canadian Cancer Society, Canadian Institutes for Health Research, Canada Foundation for Innovation, Genome Canada, the National Institutes of Health (U.S.) and the Department of Defense (U.S.). “The most exciting aspect of my career path has been its never-ending unpredictability.”
Top of page
Edith P. Mitchell, MD"Plan and keep your goals in mind. Find individuals who can give advice and serve as mentors, but also find sponsors who will help open doors. Prepare yourself and take advantage of multiple opportunities."
Clinical Professor of Medicine and Medical Oncology; Department of Medical Oncology; Director
Center to Eliminate Cancer Disparities, Sidney Kimmel Cancer Center at Jefferson
Dr. Mitchell is board certified in internal medicine and medical oncology and is clinical professor, Department of Medicine and Medical Oncology at Sidney Kimmel Medical College at Thomas Jefferson University and associate director for Diversity Programs and director of the Center to Eliminate Cancer Disparities for the Sidney Kimmel Cancer Center at Thomas Jefferson University.
Dr. Mitchell's research in breast, colorectal, and pancreatic cancers and other GI malignancies involves new drug evaluation and chemotherapy, development of new therapeutic regimens, chemoradiation strategies for combined modality therapy, patient selection criteria and supportive care for patients with gastrointestinal cancer. She has spent her medical career assisting individuals in medically underserved areas realize changes in lifestyle can dramatically impact cancer care. Through her work, Dr. Mitchell has demonstrated the importance of community service and outreach especially to individuals unable to obtain more conventional medical advice.
Dr. Mitchell holds leadership positions in ASCO, serves on the NCI Review Panel, the Cancer Investigations Review Committee, the Clinical Trials and Translational Research Advisory Committee, the NIH Council of Councils, is Co-Chair of the NCI Disparities Committee and served on the NCI's Blue Ribbon Panel. She was the 116th president of the National Medical Association. Dr. Mitchell is also a retired United States Air Force Brigadier General, having served in the Air National Guard.
Top of page
Jeffery Moscow, MD
National Cancer Institute
Dr. Moscow joined the Investigational Drug Branch (IDB) in January 2014 after serving part-time since August 2012. He is a graduate of Harvard University and the Geisel School of Medicine at Dartmouth. He completed his pediatric residency at the University of Texas Southwestern in Dallas and a fellowship in pediatric hematology-oncology in the Pediatric Oncology Branch, NCI. Prior to joining CTEP, he was Children's Miracle Network professor of pediatrics, chief of pediatric hematology-oncology, vice chair of pediatrics, and co-leader of the Experimental Therapeutics Program of the Markey Cancer Center, all at the University of Kentucky. His IDB portfolio includes lapatinib, osimertinib, dinutuximab, MEDI570 and anetumab. Dr. Moscow is also the program director of both the Early Drug Development Opportunity Program, a program that helps involve all NCI Cancer Centers in clinical ETCTN research and PDXNet, a Precision Medicine initiative to systematically incorporate patient-derived models into NCI's preclinical drug development efforts. In addition, Dr. Moscow has a laboratory research program in the Urologic Oncology Branch in the NCI Center for Cancer Research that is focused on targeting metabolic pathways for cancer therapy.
Top of page
C. Kent Osborne, MD
Director, Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Dr. Osborne was born in St. Louis, Missouri and received his AB and his MD from the University of Missouri, both with honors. He completed his internship and residency at Johns Hopkins and followed this with three years as a Clinical Associate at the Medicine Branch of the National Cancer Institute. He was a faculty member at the University of Texas Health Science Center from 1977 until 1999 and became chief of medical oncology in 1992. In 1999, Dr. Osborne moved to Baylor College of Medicine to direct a new Breast Center and in 2004 he, in addition, was named director of the Dan L. Duncan Cancer Center at Baylor.
Dr. Osborne's research interests have focused on the biology and treatment of breast cancer. He has published extensively on the role of growth factors in breast cancer pathogenesis, and he has also investigated the mechanisms of action and resistance to ER and HER2 targeted therapies in breast cancer. Dr. Osborne currently directs the Baylor Breast Cancer Specialized Program of Research Excellence Grant. Dr. Osborne has authored more than 400 manuscripts dealing with the biology and treatment of breast cancer.
"Dr. Osborne is a physician scientist who has focused on breast cancer his entire career. His research interests include understanding the biology of breast cancer and then developing new treatment approaches for the disease."
William Pao, MD, PhD
Head of Pharma Research & Early Development (pRED)
Dr. Pao is one of the world's leading molecular oncologists, with world-class expertise in targeted cancer therapeutics, translational medicine, molecular diagnostics, and personalized healthcare strategies using cancer genomics.
Dr. Pao came to Roche pRED from Vanderbilt University Medical Center, where he was professor of medicine, director of the Division of Hematology and Oncology, and director of personalized cancer medicine. He also played leadership roles across a number of other departments, including cancer biology and pathology/microbiology/immunology. He was previously a faculty member at Memorial Sloan-Kettering Cancer Center in the Human Oncology and Pathogenesis Program. Dr. Pao earned his MD and PhD degrees from Yale University, where he investigated the role of gamma-delta T cells in mice.
Dr. Pao and his research team have contributed to over 170 publications in fields including cancer biology, cancer genomics and cancer treatment.
Edith A. Perez, MD
Professor of Medicine at Mayo Clinic and Director of the Mayo Clinic Breast Cancer Translational Genomics Program
Mayo Clinic Cancer Center
Dr. Perez is an internationally recognized translational researcher and cancer specialist, professor of medicine at Mayo Clinic and director of the Mayo Clinic Breast Cancer Translational Genomics Program. Experiences include leadership in academic and biopharmaceutical environments, added to focused philanthropic endeavors.
Dr. Perez’s career has spanned from her medical school in Puerto Rico, electives while student at Mt. Sinai Hospital in New York, residency and fellowship training in California, academic career at Mayo Clinic, and a three-year period of experience in the biopharmaceutical industry (vice president BioOncology U.S. Medical Affairs, Cancer Immunotherapy Governance Committee, Medical Leadership Team, Joint Oncology Leadership Team at Genentech). Moreover, she has been involved in NCI, NIH, IOM, ASCO, AACR committees, added to volunteering in philanthropic and advocacy groups. She is frequently invited to lecture at national and international meetings across the globe. Known for her integration of basic science, trial work, and patient management – Dr. Perez is often a keynote speaker who inspires the health care professional audiences and patients. She has been honored by receiving many scientific and humanitarian awards over the years and is known for her strategic vision in designing innovative clinical trials, her passion/voice of the patient, and her strong team leadership.
Dr. Perez added to academic and biomedical industry pursuits, Dr. Pereze is the co-developer of the 26.2 National Marathon to Finish Breast Cancer (breastcancermarathon.com), with goals to raise funds for underserved women and genomics/immunologic translational cancer research. More than 10,000 families have received assistance from the proceeds and more than $ 4 million raised for cancer research.
Dr. Perez earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. She served as general internist in the Division of National Health Services Corps, Los Angeles, and completed her hematology/oncology fellowship at the University of California, Davis School of Medicine. Dr. Perez also pursued additional leadership, management, and executive development at The Wharton School of the University of Pennsylvania and Harvard Kennedy School in Boston. Dr. Perez is board certified in internal medicine, medical oncology and hematology.
“Be engaged, be part of the solution. Lead from where you are, professionally and personally.”
Dr. Srivastava is senior scientific officer and chief of the Cancer Biomarkers Research Group in the Division of Cancer Prevention, National Cancer Institute. Dr. Srivastava is an internationally recognized leader in cancer biomarker research. He is best known for his seminal contributions to improving systems approach to biomarker discovery, development and validation. In 2000, Dr. Srivastava developed and implemented a novel approach to collaborative clinical research on cancer biomarkers through the establishment of the Early Detection Research Network (EDRN
), a flagship program at the National Cancer Institute, National Institutes of Health.
Dr. Srivastava is the founding editor-in chief of the journal, Cancer Biomarkers
, published by the IOS press and serves as associate editor and reviewer for several internationally known journals. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. He has edited several monographs and five books: Early Detection of Cancer: Molecular Markers
, published by the Futura Publishing Company in 1995 and Molecular Pathology of Cancer
, published by IOS Press, Amsterdam in 1999; Informatics in Proteomics
(2005) published by Francis and Taylor, New York; Translational Pathology of Early Cancer
(2012), published by the IOS Press and Biomarkers in Cancer Screening and Early Detection
, published by Wiley, New York, 2017.
Dr. Srivastava has received numerous NCI and NIH awards for his leadership in biomarker research and received a Team Science Award for Informatics by the Jet Propulsion Laboratory, NASA for his visionary and innovative use of NASA Data System Technologies in biomedical science. In 2016, he received a Cancer Prevention Distinguished Alumni Award for his accomplishments and mentoring of fellows. Recently, he was awarded Distinguished Public Service Award (2016) by the American Pancreatology Association and a Distinguished Clinical and Translational Proteomics Award (2017) by HUPO International. He was featured in Wired
magazine in August 2003 for his leadership in cancer diagnostics. “If everything comes easy in your life, it is boring. I strive for challenges which make me resilient and determined.”